Impact Biomedical IBO
NYSE IBO
$5.32 -0.14 (-2.56%)
At close: Oct 2, 2026 · 4:00 PM EDT

Impact Biomedical (IBO) Return on Sales [ROS] (2022 - 2026)

Updated

Impact Biomedical's Return on Sales [ROS] was -23400.00% in Q2 2026, down 6928.57 percentage points from -16471.43% a year earlier but up 9300.00 percentage points from the prior quarter.

Analysis

Impact Biomedical (IBO) Return on Sales [ROS] (2022 - 2026) Analysis & Trends

On a trailing twelve-month basis, Impact Biomedical's Return on Sales [ROS] was -14548.57% through Jun 30, 2026, up 37242.66 percentage points year-over-year; for FY2022, it came in at -6808.00%.

  • Quarterly Return on Sales [ROS] has moved between -32700.00% (Q1 2026) and -1500.00% (Q2 2022) over five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 28.21%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 37.86%
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -3.52%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 32.97%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 20.57%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 34.95%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -133.21%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 28.37%
10 Impact Biomedical 573.61 Mn 576.81 Mn 2,000.00 -23,400.00%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -23,400.00%
Mar 31, 2026 -32,700.00%
Sep 30, 2025 -5,266.67%
Jun 30, 2025 -16,471.43%
Jun 30, 2022 -1,500.00%
API Access

Impact Biomedical Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=IBO&period=max&api_key=YOUR_API_KEY